LGVN vs MESO vs NKTR vs BCLI vs PLUR

For growth investors, Pluri Inc.

(PLUR) is the stronger pick with 309. 8% revenue growth year-over-year, versus -49. 9% for Longeveron Inc. (LGVN). Brainstorm Cell Therapeutics Inc. (BCLI) offers the better valuation at 0. 3x trailing P/E, making it the more compelling value choice. Analysts rate Mesoblast Limited (MESO) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Mesoblast Limited (MESO) delivered a total return of +6.

0%, compared to -98. 5% for Brainstorm Cell Therapeutics Inc. (BCLI). Over 10 years, the gap is even starker: MESO returned -2. 1% versus LGVN's -98. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Longeveron Inc.

(LGVN) is the lower-risk stock at 0. 95β versus Nektar Therapeutics's 1. 85β — meaning NKTR is approximately 94% more volatile than LGVN relative to the S&P 500. On balance sheet safety, Longeveron Inc. (LGVN) carries a lower debt/equity ratio of 15% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Pluri Inc.

(PLUR) is pulling ahead at 309. 8% versus -49. 9% for Longeveron Inc. (LGVN). On earnings-per-share growth, the picture is similar: Brainstorm Cell Therapeutics Inc. grew EPS 148. 9% year-over-year, compared to -20. 6% for Longeveron Inc.. Over a 3-year CAGR, PLUR leads at 78. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Brainstorm Cell Therapeutics Inc.

(BCLI) is the more profitable company, earning 1369% net margin versus -1893. 6% for Longeveron Inc. — meaning it keeps 1369% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NKTR leads at -236. 8% versus -1942. 2% for LGVN. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Longeveron Inc.

(LGVN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 95)). Nektar Therapeutics (NKTR) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LGVN: -98. 9%, NKTR: -59. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LGVN is a small-cap quality compounder stock; MESO is a small-cap high-growth stock; NKTR is a small-cap quality compounder stock; BCLI is a small-cap deep-value stock; PLUR is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.